The global schizoaffective drug market size was estimated to be USD 8.10 billion in 2023 and is expected to reach USD 15.32 billion by 2034 with a CAGR of 5.97% during the forecast period 2024-2034. The increasing prevalence of schizoaffective disorder, advancements in drug development, expanding mental health awareness, government initiatives and policies, technological advancements in diagnosis, patient-centric treatment approaches, and collaborations and partnerships will drive the market growth.
The schizoaffective disorder medication market is expanding due in part to the increasing frequency and incidence of this illness. More people may receive diagnoses as mental health awareness grows and diagnostic techniques advance, increasing the need for efficient drugs. For instance, in November 2023, the FDA approved Invega Trinza, a long-acting injectable treatment for schizophrenia and schizoaffective disorder, by Johnson & Johnson.
By therapeutic class, the second-generation antipsychotics segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the increased adoption of these medications, driven by their efficacy in managing both psychotic and mood symptoms, as well as their relatively favorable side effect profiles compared to first-generation antipsychotics. For instance, in October 2023, Pfizer Inc. and Acadia Pharmaceuticals will conclude the Phase 3 study for ACP-527, a long-acting injectable antipsychotic for schizophrenia and schizoaffective disorder. Additionally, the third-generation antipsychotics segment is predicted to grow at the fastest CAGR during the forecast period owing to the continual advancements in drug development, characterized by improved efficacy, reduced side effects, and a focus on addressing specific neurobiological targets associated with schizoaffective disorder.
By treatment, the oral segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the convenience and widespread patient preference for oral formulations, as well as the well-established efficacy and safety profiles of oral medications. For instance, in November 2023, Medicare Part B coverage will be added to the Abilify MyCite program by Eli Lilly and Company, therefore improving access for individuals suffering from schizophrenia and schizoaffective disorder. Additionally, the injectables segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the advantages associated with long-acting injectable formulations in enhancing treatment adherence, ensuring consistent therapeutic levels, and addressing challenges related to medication compliance often faced in schizoaffective disorder.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the centralized nature of treatment for severe mental health conditions, with hospitals serving as key hubs for the diagnosis, management, and ongoing care of individuals with schizoaffective disorders. For instance, in September 2023, Bristol Myers Squibb and Pear Therapeutics will collaborate to develop a digital therapy application for schizophrenia, which is presently in the early phases of development. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital healthcare platforms, rising consumer preference for convenient and accessible medication procurement, and the global expansion of e-commerce in the pharmaceutical sector.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased awareness, and understanding of mental health issues, robust research and development activities, and a higher prevalence of diagnosed cases of schizoaffective disorder. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of mental health disorders, a growing population, rising awareness, improving access to healthcare, and ongoing efforts to reduce the stigma associated with psychiatric conditions. For instance, Novartis AG will introduce Xeplion (paliperidone palmitate), a long-acting injectable treatment for schizophrenia and schizoaffective disorder, into the European market in August 2023.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The schizoaffective disorder medication market is expanding due in part to the increasing frequency and incidence of this illness. More people may receive diagnoses as mental health awareness grows and diagnostic techniques advance, increasing the need for efficient drugs. For instance, in November 2023, the FDA approved Invega Trinza, a long-acting injectable treatment for schizophrenia and schizoaffective disorder, by Johnson & Johnson.
By therapeutic class, the second-generation antipsychotics segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the increased adoption of these medications, driven by their efficacy in managing both psychotic and mood symptoms, as well as their relatively favorable side effect profiles compared to first-generation antipsychotics. For instance, in October 2023, Pfizer Inc. and Acadia Pharmaceuticals will conclude the Phase 3 study for ACP-527, a long-acting injectable antipsychotic for schizophrenia and schizoaffective disorder. Additionally, the third-generation antipsychotics segment is predicted to grow at the fastest CAGR during the forecast period owing to the continual advancements in drug development, characterized by improved efficacy, reduced side effects, and a focus on addressing specific neurobiological targets associated with schizoaffective disorder.
By treatment, the oral segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the convenience and widespread patient preference for oral formulations, as well as the well-established efficacy and safety profiles of oral medications. For instance, in November 2023, Medicare Part B coverage will be added to the Abilify MyCite program by Eli Lilly and Company, therefore improving access for individuals suffering from schizophrenia and schizoaffective disorder. Additionally, the injectables segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the advantages associated with long-acting injectable formulations in enhancing treatment adherence, ensuring consistent therapeutic levels, and addressing challenges related to medication compliance often faced in schizoaffective disorder.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global schizoaffective drug market in 2023 owing to the centralized nature of treatment for severe mental health conditions, with hospitals serving as key hubs for the diagnosis, management, and ongoing care of individuals with schizoaffective disorders. For instance, in September 2023, Bristol Myers Squibb and Pear Therapeutics will collaborate to develop a digital therapy application for schizophrenia, which is presently in the early phases of development. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital healthcare platforms, rising consumer preference for convenient and accessible medication procurement, and the global expansion of e-commerce in the pharmaceutical sector.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increased awareness, and understanding of mental health issues, robust research and development activities, and a higher prevalence of diagnosed cases of schizoaffective disorder. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of mental health disorders, a growing population, rising awareness, improving access to healthcare, and ongoing efforts to reduce the stigma associated with psychiatric conditions. For instance, Novartis AG will introduce Xeplion (paliperidone palmitate), a long-acting injectable treatment for schizophrenia and schizoaffective disorder, into the European market in August 2023.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Therapeutic Class, Treatment, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Schizoaffective Drug Market Report 2023 - 2034
Schizoaffective Drug Market Analysis & Forecast by Therapeutic Class 2023 - 2034 (Revenue USD Bn)
- Second-generation Antipsychotics
- Third-generation Antipsychotics,
- Other Therapeutic Classes
Schizoaffective Drug Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Oral
- Injectables
Schizoaffective Drug Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Retail Pharmacies
- Online Pharmacies
Schizoaffective Drug Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Schizoaffective Drug Market: Therapeutic Class Estimates & Trend Analysis
8. Schizoaffective Drug Market: Treatment Estimates & Trend Analysis
9. Schizoaffective Drug Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Schizoaffective Drug Market
12. Europe Global Schizoaffective Drug Market
13. Asia Pacific Global Schizoaffective Drug Market
14. Latin America Global Schizoaffective Drug Market
15. MEA Global Schizoaffective Drug Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca
- Bristol Myers Squibb
- Novartis AG
- GlaxoSmithKline plc (GSK)
- Otsuka Pharmaceutical Co. Ltd.
- Lundbeck
- Sunovion Pharmaceuticals Inc.
- Alkermes plc
- Allergan (now part of AbbVie)
- Sumitomo Dainippon Pharma Co. Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 8.1 Billion |
| Forecasted Market Value ( USD | $ 15.32 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
